US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Iambic Therapeutics Inc. (IAM): Ark Invest Backs AI-Driven Drug Platform, Sets Terms for IPO

IPOs and Secondary Offerings

Equity Capital Markets

Iambic Therapeutics / Equity Capital Markets

<ul>
<li>AI is the differentiator: Iambic integrates proprietary AI models, automated laboratories and experimental feedback into a continuous drug-discovery platform.</li>
<li>Credible industry relationships: Collaborations involving AbbVie, Takeda, Lundbeck, NVIDIA and other notable companies strengthen the platform’s commercial and scientific credibility.</li>
<li>Market execution remains uncertain: The AI narrative could attract investor attention, but recent biotech IPO weakness raises the bar for a strong debut.</li>
</ul>


AI is the differentiator: Iambic integrates proprietary AI models, automated laboratories and experimental feedback into a continuous drug-discovery platform.
Credible industry relationships: Collaborations involving AbbVie, Takeda, Lundbeck, NVIDIA and other notable companies strengthen the platform’s commercial and scientific credibility.
Market execution remains uncertain: The AI narrative could attract investor attention, but recent biotech IPO weakness raises the bar for a strong debut.


Iambic Therapeutics Inc. (IAM): Bringing an AI Twist to the Biotech IPO Market